Hyperuricemia with heart failure
Conditions
Interventions
Group A: administering topiroxostat with minimum amount of 20 mg twice a day (after breakfast), and gradually increase the amount every four weeks aiming for blood uric acid level 6.0 mg/dL or lower
Sponsors
Dokkyo Medical University Department of Cardiovascular Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are included in this study. 1. Patients with hyperuricemia (untreated with uric acid level 7.0 mg/dl or above, or currently on medication) with a history of heart failure (however BNP is 40 pg/ml or above according to the Japan Heart Failure Society) 2. Not using any medication for hyperuricemia for more than four weeks before the study 3. Being able to provide written informed consent 4. 20 years of age or older, and younger than 85 years of age at time of providing their written informed consent
Exclusion criteria
Exclusion criteria: Patients who fall into any of the following criteria are excluded from participating in the study. 1.Have a history of hypersensitivity to the test drug 2.Currently on medication of mercaptopurine hydrate or azathioprine 3.Currently have a severe liver failure (AST or ALT level is doubled from the standard values provided by each hospital/clinic) 4.Complicated with chronic liver disease, malignant tumor, active infection, or inflammatory disease 5.Currently have gout arthritis or the disease is cured for less than two weeks 6.Currently have nephrolithiasis or on treatment 7.eGFR is below 30 ml/min/1.73 square meters (CCr 30ml/min) 8.Currently have acute heart failure 9.After acute exacerbation improvement in chronic heart failure is less than two weeks 10. Currently pregnant or possibly conceived a child, or brest feeding 11.Other conditions that physicians judge to be inappropriate to be in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change in NT-proBNP from baseline to the 24th week | — |
Countries
Japan
Contacts
Public ContactHiroki Takayama
Soiken Inc. Clinical Study Support Division
Outcome results
None listed